Zymeworks Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
290
- Stock Symbol
-
ZYME
- Investments
-
1
- Share Price
-
$12.19
- (As of Thursday Closing)
Zymeworks General Information
Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Contact Information
Website
www.zymeworks.comCorporate Office
- 114 East 4th Avenue
- Suite 800
- Vancouver, British Columbia V5T 1G4
- Canada
Corporate Office
- 114 East 4th Avenue
- Suite 800
- Vancouver, British Columbia V5T 1G4
- Canada
Zymeworks Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.19 | $12.10 | $6.01 - $13.14 | $865M | 71M | 679K | -$1.51 |
Zymeworks Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 281,875 | 458,284 | 359,058 | 485,454 |
| Revenue | 62,705 | 76,012 | 412,482 | 26,680 |
| EBITDA | (122,397) | (121,642) | 143,642 | (204,741) |
| Net Income | (112,508) | (118,674) | 124,341 | (211,843) |
| Total Assets | 515,634 | 580,880 | 648,725 | 389,132 |
| Total Debt | 20,064 | 26,722 | 28,113 | 32,333 |
Zymeworks Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zymeworks Comparisons
Industry
Financing
Details
000000
000000
Zymeworks Competitors (45)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioAtla | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| Biostax Corp | Corporation | Orlando, FL | 0 | 000000000000 | ||
| MediGene | Formerly VC-backed | Planegg, Germany | 00 | 00000 | 000000000 | 00000 |
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | 000 | 00000 | 000000000 | 00000 |
| Molecular Partners | Formerly VC-backed | Zurich, Switzerland | 000 | 00000 | 00000000 | 00000 |
Zymeworks Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zymeworks Patents
Zymeworks Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024056808-A | Methods of using bispecific antigen-binding construct targeting her2 for treatment of biliary tract cancers | Pending | 31-May-2019 | 000000000 | |
| US-11072658-B2 | Anti-pd-1/lag3 bispecific antibodies | Active | 01-Feb-2018 | 00000000000 | 00 |
| EP-3746481-A1 | Anti-pd-1/lag3 bispecific antibodies | Pending | 01-Feb-2018 | 00000000000 | |
| US-20190233518-A1 | Anti-pd-1/lag3 bispecific antibodies | Active | 01-Feb-2018 | 00000000000 | |
| US-20200048371-A1 | Tumor antigen presentation inducer constructs and uses thereof | Inactive | 31-Mar-2017 | C07K16/468 |
Zymeworks Executive Team (24)
| Name | Title | Board Seat |
|---|---|---|
| Kenneth Galbraith | Chief Executive Officer & Chief Financial Officer, Finance | |
| Paul Moore | Chief Scientific Officer | |
| Jeffrey Smith MD | Chief Medical Officer & Executive Vice President | |
| Jeffrey Smith | Executive Vice President & Chief Medical Officer | |
| Lucas Donigian | Vice President of Business & Commercial Development |
Zymeworks Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alessandra Cesano Ph.D | Self | Board Member | 000 0000 |
| Carlos Campoy | Self | Board Member | 000 0000 |
| Hollings Renton | Self | Board Member | 000 0000 |
| Kelvin Neu Ph.D | Self | Board Member | 000 0000 |
| Lota Zoth | Self | Chairman of the Board | 000 0000 |
Zymeworks Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Zymeworks Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kairos Therapeutics | 18-Mar-2016 | 0000000000 | 000.00 | Biotechnology | 000 00000 |
Zymeworks ESG
Risk Overview
Risk Rating
Updated March, 20, 2024
29.01 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Zymeworks FAQs
-
When was Zymeworks founded?
Zymeworks was founded in 2003.
-
Who is the founder of Zymeworks?
Ali Tehrani Ph.D is the founder of Zymeworks.
-
Who is the CEO of Zymeworks?
Kenneth Galbraith is the CEO of Zymeworks.
-
Where is Zymeworks headquartered?
Zymeworks is headquartered in Vancouver, Canada.
-
What is the size of Zymeworks?
Zymeworks has 290 total employees.
-
What industry is Zymeworks in?
Zymeworks’s primary industry is Biotechnology.
-
Is Zymeworks a private or public company?
Zymeworks is a Public company.
-
What is Zymeworks’s stock symbol?
The ticker symbol for Zymeworks is ZYME.
-
What is the current stock price of Zymeworks?
As of 12-Sep-2024 the stock price of Zymeworks is $12.19.
-
What is the current market cap of Zymeworks?
The current market capitalization of Zymeworks is $865M.
-
What is Zymeworks’s current revenue?
The trailing twelve month revenue for Zymeworks is $62.7M.
-
Who are Zymeworks’s competitors?
BioAtla, Biostax Corp, MediGene, Dynavax Technologies, and Molecular Partners are some of the 45 competitors of Zymeworks.
-
What is Zymeworks’s annual earnings per share (EPS)?
Zymeworks’s EPS for 12 months was -$1.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
